← All trials
NCT04728802
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2021
- Primary completion
- Apr 15, 2021
- Completion date
- Apr 15, 2021
- First posted
- Jan 28, 2021
- Last posted
- Jun 24, 2021
- Enrollment
- 645
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Applied Biology, Inc.Lead sponsor
- Applied Biology, Inc.Overall official - principal investigator
- Applied Biology, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.